This may allow the reduction of burdensome clinical visits for MDS patients and the Ki-67 proliferation index may become an additional prognostic parameter in the WHO-classification-based prognostic scoring system and IPSS-R for MDS patients. This evidence concerns the gene MKI67 and myelodysplastic syndrome.